Kalvista Pharm SEC Filings

KalVista Pharmaceuticals, Inc. insider activity: the company’s Chief Executive Officer and director reported routine equity award activity. On 11/17/2025, the reporting person acquired 9,364 shares of common stock through the vesting and settlement of restricted stock units (coded “M”), increasing directly held common shares to 408,345. On 11/18/2025, 4,466 shares of common stock were sold at a weighted average price of $14.4794 per share, leaving 403,879 shares of common stock directly owned.

The sale was made to cover tax withholding obligations arising from RSU vesting under a “sell to cover” arrangement and is described as non-discretionary. Related RSU awards provided common shares at no cash exercise price, with portions vesting in equal installments on quarterly anniversaries of their respective vesting commencement dates, subject to continued service.

KalVista Pharmaceuticals, Inc. insider trading report: The company’s Chief Development Officer filed a Form 4 detailing routine equity award activity. On 11/17/2025, the officer acquired 4,205 shares of KalVista common stock following the vesting and settlement of restricted stock units (RSUs), which convert to common stock on a one-for-one basis for no cash consideration. On 11/18/2025, 2,683 shares were sold in a broker-assisted “sell to cover” transaction at a weighted average price of $14.4794 per share to satisfy tax withholding obligations tied to the RSU vesting, described as non-discretionary. After these transactions, the officer beneficially owned 133,574 shares of KalVista common stock, held directly.

KalVista Pharmaceuticals' (KALV) Chief Medical Officer reported equity activity involving restricted stock units and related share sales. On 11/17/2025, 6,447 shares of common stock were acquired through the vesting and settlement of restricted stock units, increasing direct holdings to 128,952 shares. On 11/18/2025, 3,075 shares were sold at a weighted average price of $14.4795 per share to cover tax withholding obligations from the RSU vesting, a non-discretionary "sell to cover" transaction, leaving 125,877 shares directly owned.

The filing also shows RSU awards converting into 2,419 and 4,028 shares of common stock at a conversion price of $0 per RSU. One RSU grant vests in 1/16th increments each quarterly anniversary of its vesting commencement date, and another in 1/12th quarterly increments, in each case conditioned on continued service.

KalVista Pharmaceuticals (KALV) reported insider activity by CEO Benjamin L. Palleiko. On 11/11/2025, 7,120 RSUs vested and were settled into common stock. On 11/12/2025, he sold 3,328 shares at $11.55 to cover tax withholding tied to the RSU settlement. Following these transactions, directly held common stock was 398,981 shares, and derivative securities beneficially owned were 106,800. The RSU award vests in equal quarterly installments beginning November 11, 2025.

KalVista Pharmaceuticals (KALV) reported its first commercial quarter following EKTERLY (sebetralstat) approvals, recording product revenue, net of $13.7 million for the three months ended September 30, 2025. Operating expenses rose with the launch, led by S,G&A of $46.5 million and R&D of $12.0 million, driving an operating loss of $46.1 million and a net loss of $49.5 million (basic and diluted loss per share of $0.92).

Liquidity strengthened: cash and cash equivalents were $243.5 million and marketable securities were $65.7 million. The company issued $143.8 million aggregate principal of convertible notes (balance sheet carrying amount $139.0 million) and reported a royalty obligation with a $125.0 million net carrying amount tied to its DRI agreement. Deferred revenue was $11.5 million from the Kaken upfront. EKTERLY received U.S., UK, EU, Switzerland and Australia approvals in 2025, with commercial sales initiated in the U.S. and Germany.

KalVista Pharmaceuticals (KALV) furnished an update on its latest results. The company reported financial results for the quarter ended September 30, 2025 and provided a related press release as Exhibit 99.1 to this Form 8-K.

The information under Item 2.02, including Exhibit 99.1, is expressly stated as “furnished” and not “filed” under Section 18 of the Exchange Act, and is not incorporated by reference unless specifically noted in a future filing.

KalVista Pharmaceuticals insider grant: An officer, Chief Operations Officer Arif Bilal, was granted 100,000 stock options exercisable at $11.49 per share. The option award vests over a four-year schedule with 25% vesting on 10/08/2026 and the remainder vesting monthly thereafter; the options expire on 10/07/2035. Following this transaction the reporting person beneficially owns 100,000 underlying shares on a direct basis. The filing was reported on 10/08/2025.

Arif Bilal, listed as Chief Operations Officer and a director of KalVista Pharmaceuticals, Inc. (KALV), filed an initial Form 3 reporting that no securities are beneficially owned as of the event date 10/06/2025. The filing was signed by an attorney-in-fact on 10/08/2025. This Form 3 records a disclosure obligation under Section 16; instead of listing share ownership or derivative positions, it indicates the reporting person currently holds zero reportable equity or derivative interests.

KalVista Pharmaceuticals (KALV) disclosed an employment agreement for a newly named executive, Mr. Arif, detailing compensation and termination protections. The agreement sets a $520,000 base salary and an annual bonus target equal to 40% of base salary. Mr. Arif will receive stock options to purchase 100,000 shares that vest over four years with 1/4 vesting after one year and thereafter 1/48th monthly vesting, subject to continued service.

If terminated by the company without cause or by Mr. Arif for good reason, he is entitled to a lump-sum payment equal to 12 months of base salary and 12 months of COBRA reimbursement. Within two years after a defined change in control, similar termination triggers (company without cause or employee for good reason) add a lump-sum payment equal to 12 months of base salary, a lump-sum equal to his full target bonus for the fiscal year, 12 months of COBRA reimbursement, and full vesting of outstanding unvested equity awards (with performance awards deemed at target or actual if determinable).

The filing includes a Form of Indemnification Agreement reference and notes a press release dated October 6, 2025, signed by CFO Brian Piekos.